Across TCGA pan-cancer cohorts, ARHGEF28 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ARHGEF28’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARHGEF28 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGEF28 is over-expressed in tumor, although a few such as LUAD and PDAC show the opposite, repressed pattern.

LUAD, PDAC, and LSCC are the cancer types where ARHGEF28 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF28 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	−0.343	<.001	7	view →
PDAC	Female	II,III,IV	−0.508	<.001	4	view →
LSCC	Female	All	−0.240	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ARHGEF28 RNA expression & survival · all ARHGEF28 data types